- Home
- RPRX vs EXAS Comparison
RPRX vs EXAS Comparison
Compare RPRX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | EXAS |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 19.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RPRX | EXAS |
|---|---|---|
| Price | $45.16 | $103.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | $47.75 | ★ $84.27 |
| AVG Volume (30 Days) | ★ 4.2M | 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.10 | $19.40 |
| Revenue Next Year | $5.02 | $13.54 |
| P/E Ratio | $25.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.66 | $38.81 |
| 52 Week High | $46.14 | $103.54 |
Technical Indicators
Market Signals| Indicator | RPRX | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 73.30 | 69.20 |
| Support Level | $42.50 | $103.14 |
| Resistance Level | $46.14 | $103.87 |
| Average True Range (ATR) | 1.00 | 0.35 |
| MACD | 0.19 | -0.12 |
| Stochastic Oscillator | 82.91 | 72.08 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.